Factor VIII gene therapy - Cell Genesys

Drug Profile

Factor VIII gene therapy - Cell Genesys

Latest Information Update: 18 Jun 2003

Price : $50

At a glance

  • Originator Cell Genesys; Salk Institute
  • Class Blood coagulation factors; Coagulants
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haemophilia A

Most Recent Events

  • 18 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) have been added to the Gene Therapy and Haematological therapeutic trials section
  • 04 Feb 2003 Discontinued - Preclinical for Haemophilia A in USA (unspecified route)
  • 28 Jun 2002 A preclinical study has been added to the pharmacodynamic section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top